CP and COVID-19: Therefore, the novelty of the study was: (i) to identify SARS-CoV-2 mutations and variants in Turkish COVID-19 cases, (ii) to evaluate the susceptibility rate of identified variants to anti-SARS-CoV-2 mAb drugs, (iii) to evaluate the potential neutralizing efficacy of CP obtained from naturally infected cases and VP from vaccinated individuals against these variants with a newly designed web tool for SARS-CoV-2 diagnosis.